

Valter Gattei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/446923/publications.pdf>

Version: 2024-02-01

325
papers

11,491
citations

36303

51
h-index

38395

95
g-index

327
all docs

327
docs citations

327
times ranked

9931
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. <i>Leukemia</i> , 2022, 36, 271-274. | 7.2 | 4 |
| 2 | Elastin Microfibril Interfacer1 (EMILIN1) is an alternative prosurvival VLA4 ligand in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 181-190. | 1.7 | 3 |
| 3 | KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders. <i>Cancers</i> , 2022, 14, 666. | 3.7 | 8 |
| 4 | Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline <sc>ADMIRE</sc> and <sc>ARCTIC</sc> trials: A comprehensive assessment of prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, . | 4.1 | 1 |
| 5 | Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond. <i>Cancers</i> , 2022, 14, 2997. | 3.7 | 5 |
| 6 | Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome. <i>British Journal of Haematology</i> , 2022, 198, 1016-1022. | 2.5 | 10 |
| 7 | Integrin Signaling Shaping BTK-Inhibitor Resistance. <i>Cells</i> , 2022, 11, 2235. | 4.1 | 3 |
| 8 | Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. <i>Haematologica</i> , 2021, 106, 2345-2353. | 3.5 | 8 |
| 9 | Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238. | 7.2 | 17 |
| 10 | <sc><i>CDKN1B</i></sc> mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. <i>Journal of Pathology</i> , 2021, 253, 234-245. | 4.5 | 12 |
| 11 | Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499. | 2.2 | 5 |
| 12 | Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171. | 4.1 | 10 |
| 13 | Hepatitis C virus-associated indolent B-cell lymphomas: A review on the role of the new direct antiviral agents therapy. <i>Hematological Oncology</i> , 2021, 39, 439-447. | 1.7 | 6 |
| 14 | Hepatitis C virus-associated non-Hodgkin lymphomas: the endless history. <i>Minerva Medica</i> , 2021, 112, 215-227. | 0.9 | 3 |
| 15 | Hepatitis C virus-related cryoglobulinemic vasculitis. <i>Minerva Medica</i> , 2021, 112, 175-187. | 0.9 | 8 |
| 16 | <sc><i>TP53</i></sc> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310. | 4.1 | 8 |
| 17 | Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC). <i>Viruses</i> , 2021, 13, 1032. | 3.3 | 19 |
| 18 | Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab+bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272. | 4.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?. <i>Clinical Cancer Research</i> , 2021, 27, 4462-4464. | 7.0 | 0 |
| 20 | TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575. | 7.0 | 23 |
| 21 | Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574. | 1.7 | 9 |
| 22 | COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2021, 39, 712-714. | 1.7 | 17 |
| 23 | Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network. <i>HemaSphere</i> , 2021, 5, e639. | 2.7 | 0 |
| 24 | Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?. <i>Cells</i> , 2021, 10, 98. | 4.1 | 23 |
| 25 | SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. <i>Haematologica</i> , 2021, 106, 3125-3135. | 3.5 | 12 |
| 26 | Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage. <i>Blood Advances</i> , 2021, 5, 4890-4900. | 5.2 | 7 |
| 27 | A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. <i>Viruses</i> , 2021, 13, 2249. | 3.3 | 42 |
| 28 | HIF-1 α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054. | 3.5 | 39 |
| 29 | Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells. <i>International Journal of Pharmaceutics</i> , 2020, 574, 118895. | 5.2 | 12 |
| 30 | Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?. <i>Frontiers in Oncology</i> , 2020, 10, 593383. | 2.8 | 50 |
| 31 | Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses. <i>British Journal of Haematology</i> , 2020, 191, 775-783. | 2.5 | 20 |
| 32 | Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 698-704. | 1.7 | 3 |
| 33 | Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92. | 6.2 | 7 |
| 34 | Hepatitis C virus-related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy. <i>Autoimmunity Reviews</i> , 2020, 19, 102589. | 5.8 | 21 |
| 35 | Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020, 136, 763-766. | 1.4 | 33 |
| 36 | VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2206. | 4.1 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | <i>IGHV3-21*01</i> is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4320-4327. | 7.1 | 55 |
| 38 | TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 2498-2502. | 7.2 | 2 |
| 39 | CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254. | 1.4 | 33 |
| 40 | An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. <i>Cancers</i> , 2020, 12, 894. | 3.7 | 22 |
| 41 | Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456. | 3.5 | 64 |
| 42 | A laboratory-based scoring system predicts early treatment in Rai O chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620. | 3.5 | 15 |
| 43 | Recent news in the treatment of hepatitis B virus-related cryoglobulinemic vasculitis. <i>Minerva Medica</i> , 2020, 111, 566-572. | 0.9 | 5 |
| 44 | Mutations of the <i>Exportin 1 (XPO1)</i> Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. ĩ Training/Validation Study. <i>Blood</i> , 2020, 136, 31-32. | 1.4 | 1 |
| 45 | Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens. <i>Blood</i> , 2020, 136, 46-47. | 1.4 | 0 |
| 46 | Biallelic <i>BIRC3</i> inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. <i>British Journal of Haematology</i> , 2019, 185, 156-159. | 2.5 | 9 |
| 47 | Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. <i>Hematological Oncology</i> , 2019, 37, 368-374. | 1.7 | 13 |
| 48 | Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. <i>Hematological Oncology</i> , 2019, 37, 628-633. | 1.7 | 3 |
| 49 | Hepatitis B virus-related cryoglobulinemic vasculitis. The role of antiviral nucleot(s)ide analogues: a review. <i>Journal of Internal Medicine</i> , 2019, 286, 290-298. | 6.0 | 19 |
| 50 | A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. <i>Haematologica</i> , 2019, 104, e410-e414. | 3.5 | 5 |
| 51 | KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. <i>Leukemia</i> , 2019, 33, 2111-2115. | 7.2 | 21 |
| 52 | Transcriptomics and Immunological Analyses Reveal a Pro-Angiogenic and Anti-Inflammatory Phenotype for Decidual Endothelial Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1604. | 4.1 | 9 |
| 53 | Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS. <i>Leukemia</i> , 2019, 33, 1278-1302. | 7.2 | 10 |
| 54 | Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications. <i>Methods in Molecular Biology</i> , 2019, 1881, 101-112. | 0.9 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Expression of the transcribed ultraconserved region 70 and the related long non-coding RNA AC092652.202 has prognostic value in Chronic Lymphocytic Leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 1045-1050. | 2.5 | 10 |
| 56 | Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma. , 2019, , . | | 3 |
| 57 | EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy. <i>Blood</i> , 2019, 134, 124-124. | 1.4 | 6 |
| 58 | Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance. <i>Blood</i> , 2019, 134, 2569-2569. | 1.4 | 3 |
| 59 | Clinical Impact of Clonal and Subclonal TP53 Mutations and Deletions in Chronic Lymphocytic Leukemia: An Italian Multicenter Experience. <i>Blood</i> , 2019, 134, 480-480. | 1.4 | 12 |
| 60 | Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3031-3031. | 1.4 | 2 |
| 61 | Impaired Nodal Shrinkage and Apoptosis Lacking Define the Adverse Independent Clinical Outcome of NOTCH1 mutated Chronic Lymphocytic Leukemia (CLL) Patients in the Age of Targeted Agents (TA). <i>Blood</i> , 2019, 134, 1744-1744. | 1.4 | 0 |
| 62 | BCR-Induced VLA-4 Activation in the TCL1 Transgenic Mouse Model for Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 1730-1730. | 1.4 | 0 |
| 63 | Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab. <i>Blood</i> , 2019, 134, 5485-5485. | 1.4 | 1 |
| 64 | The VLA-4 Integrin Is Constitutively Activated in a Fraction of CD49d-Expressing Chronic Lymphocytic Leukemia Via Autonomous BCR-Mediated Signaling. <i>Blood</i> , 2019, 134, 849-849. | 1.4 | 0 |
| 65 | External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study. <i>Blood</i> , 2019, 134, 4308-4308. | 1.4 | 0 |
| 66 | A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , 2018, 103, 849-856. | 3.5 | 21 |
| 67 | Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 681-697. | 8.5 | 65 |
| 68 | NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , 2018, 182, 597-602. | 2.5 | 22 |
| 69 | PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 120-129. | 7.0 | 92 |
| 70 | Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing. <i>Leukemia</i> , 2018, 32, 685-693. | 7.2 | 29 |
| 71 | NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF- κ B pathways. <i>Leukemia</i> , 2018, 32, 654-662. | 7.2 | 31 |
| 72 | Regulation of HIF-1 α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S214. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2018, 103, 2049-2058. | 3.5 | 13 |
| 74 | Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization. <i>Medical Oncology</i> , 2018, 35, 118. | 2.5 | 18 |
| 75 | Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases. <i>Diseases (Basel)</i> , 2018, 10, 26. Tj ETQq1 1 0.784314 rgBT /Overlo | 2.5 | 26 |
| 76 | Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4396-4396. | 1.4 | 2 |
| 77 | Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4412-4412. | 1.4 | 2 |
| 78 | Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 585-585. | 1.4 | 7 |
| 79 | Abstract 906: Development of novel preclinical models of secondary resistance downstream B cell receptor in marginal zone lymphoma. , 2018, , . | | 0 |
| 80 | The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4397-4397. | 1.4 | 3 |
| 81 | The VLA-4 Integrin Is Constitutively Activated in a Subset of CD49d-Expressing CLL: A Relationship with the Autonomous BCR-Mediated Signaling?. <i>Blood</i> , 2018, 132, 5531-5531. | 1.4 | 0 |
| 82 | Intraclonal Diversification Occurs in Chronic Lymphocytic Leukemia Expressing B Cell Receptors Belonging to the IGHV4 Gene Family. <i>Blood</i> , 2018, 132, 944-944. | 1.4 | 0 |
| 83 | SF3B1 Mutations Associate with Low CD20 Expression in CLL: Another NOTCH1-Dependent Mechanism?. <i>Blood</i> , 2018, 132, 1838-1838. | 1.4 | 0 |
| 84 | Clinical Impact of Clonal and Subclonal TP53 Mutations in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 945-945. | 1.4 | 0 |
| 85 | The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. <i>Blood</i> , 2018, 132, 2890-2890. | 1.4 | 0 |
| 86 | Serum IgM/Fc μ r Interactions Inhibit BCR Signaling and Influence the Clinical Course of CLL. <i>Blood</i> , 2018, 132, 4409-4409. | 1.4 | 0 |
| 87 | KRAS, NRAS and BRAF Mutations Are Highly Enriched in TR12 Chronic Lymphocytic Leukemia and Are Associated to Shorter Time to First Treatment. <i>Blood</i> , 2018, 132, 3113-3113. | 1.4 | 0 |
| 88 | A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. <i>Blood</i> , 2018, 132, 4399-4399. | 1.4 | 0 |
| 89 | Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 107-114. | 0.8 | 11 |
| 90 | Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e305-e309. | 3.5 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Hepatitis C Virus-associated Non-Hodgkin Lymphomas. <i>Clinics in Liver Disease</i> , 2017, 21, 499-515. | 2.1 | 22 |
| 92 | NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. <i>Leukemia</i> , 2017, 31, 2407-2415. | 7.2 | 52 |
| 93 | Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S11-S12. | 0.4 | 0 |
| 94 | Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. <i>Scientific Reports</i> , 2017, 7, 7104. | 3.3 | 28 |
| 95 | Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e443-e446. | 3.5 | 11 |
| 96 | Low-dose radiotherapy in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 472-479. | 1.7 | 9 |
| 97 | High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2017, 8, 42398-42413. | 1.8 | 19 |
| 98 | CD205, a target antigen for a novel antibody drug conjugate (ADC): Evaluation of antigen expression on non-Hodgkin lymphoma (NHL). <i>Journal of Clinical Oncology</i> , 2017, 35, e14039-e14039. | 1.6 | 1 |
| 99 | Clinical impact of small subclones harboring <i>NOTCH1</i> , <i>SF3B1</i> or <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, e135-e138. | 3.5 | 34 |
| 100 | Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC. <i>Digestive and Liver Disease</i> , 2016, 48, 780-784. | 0.9 | 50 |
| 101 | CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. <i>Leukemia</i> , 2016, 30, 2011-2018. | 7.2 | 41 |
| 102 | A case of SRSF2 mutation in chronic lymphocytic leukemia. <i>Leukemia Research Reports</i> , 2016, 6, 11-14. | 0.4 | 2 |
| 103 | Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 81-90. | 1.5 | 45 |
| 104 | Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, 77-85. | 3.5 | 53 |
| 105 | Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL Letter. <i>Clinical Cancer Research</i> , 2016, 22, 3410-3411. | 7.0 | 1 |
| 106 | A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. <i>Nano Research</i> , 2016, 9, 537-548. | 10.4 | 17 |
| 107 | Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors. <i>Haematologica</i> , 2016, 101, e99-e102. | 3.5 | 28 |
| 108 | NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. <i>Leukemia</i> , 2016, 30, 182-189. | 7.2 | 74 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?. <i>Leukemia</i> , 2016, 30, 513-517. | 7.2 | 3 |
| 110 | Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. <i>Drugs of Today</i> , 2016, 52, 249. | 1.1 | 18 |
| 111 | A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2016, 7, 26346-26360. | 1.8 | 12 |
| 112 | Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia. <i>Current Cancer Drug Targets</i> , 2016, 16, 659-668. | 1.6 | 11 |
| 113 | Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options. <i>World Journal of Hepatology</i> , 2016, 8, 107. | 2.0 | 52 |
| 114 | Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4367-4367. | 1.4 | 0 |
| 115 | Low Bax/Bcl-2 Ratio and NOTCH1 Mutations Represent Powerful and Synergistic Adverse Prognostic Factors within Trisomy 12 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 3204-3204. | 1.4 | 0 |
| 116 | Mutations at 3' Untranslated Region (3'UTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 306-306. | 1.4 | 0 |
| 117 | Lack of Prognostic Significance of the Conventional and Novel Prognostic Markers in Trisomy 12 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 4354-4354. | 1.4 | 0 |
| 118 | HIF-1 α Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. <i>Blood</i> , 2016, 128, 305-305. | 1.4 | 0 |
| 119 | Comprehensive Characterization of NOTCH1 Mutational Status in Chronic Lymphocytic Leukemia: Clinical Relevance of Subclonal Mutations and Mutation Types. <i>Blood</i> , 2016, 128, 3195-3195. | 1.4 | 0 |
| 120 | The B-Cell Receptor Signaling Inhibitor Molecules CD305 and CD307b Are Markers of Favorable Prognosis in Chronic Lymphocytic Leukemia with Both Mutated and Unmutated IGHV Gene Status. <i>Blood</i> , 2016, 128, 4358-4358. | 1.4 | 1 |
| 121 | CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and independent mechanisms. <i>British Journal of Haematology</i> , 2015, 169, 286-289. | 2.5 | 26 |
| 122 | Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924. | 1.4 | 197 |
| 123 | The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential. <i>Oncotarget</i> , 2015, 6, 19381-19392. | 1.8 | 51 |
| 124 | Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis. <i>Digestive and Liver Disease</i> , 2015, 47, 613-616. | 0.9 | 3 |
| 125 | p27 ^{kip1} controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13916-13921. | 7.1 | 45 |
| 126 | CD Nomenclature 2015: Human Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology. <i>Journal of Immunology</i> , 2015, 195, 4555-4563. | 0.8 | 125 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. <i>Leukemia</i> , 2015, 29, 356-368. | 7.2 | 33 |
| 128 | Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. <i>Leukemia</i> , 2015, 29, 406-414. | 7.2 | 64 |
| 129 | The KrÄppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , 2015, 29, 503-507. | 7.2 | 84 |
| 130 | CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21. <i>Oncotarget</i> , 2015, 6, 12048-12060. | 1.8 | 18 |
| 131 | The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2015, 6, 19102-19117. | 1.8 | 18 |
| 132 | Retention of inside-out VLA-4 Integrin Activation upon B-Cell Receptor Triggering in in-Vitro and in-Vivo Ibrutinib Treated Chronic Lymphocytic Leukemia Cells: Clinical Implication. <i>Blood</i> , 2015, 126, 1708-1708. | 1.4 | 0 |
| 133 | The Concomitant High Expression of the B-Cell Receptor Signaling Inhibitor Molecules CD150, CD305, and CD307b Predicts Longer Overall Survival in the Context of Low-Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1720-1720. | 1.4 | 0 |
| 134 | Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 1718-1718. | 1.4 | 0 |
| 135 | Targeted Nanoparticles for the Delivery of Antagomir17: New Approach for the Treatment of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 5293-5293. | 1.4 | 0 |
| 136 | Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway. <i>Blood</i> , 2015, 126, 701-701. | 1.4 | 0 |
| 137 | Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. <i>PLoS ONE</i> , 2014, 9, e98818. | 2.5 | 33 |
| 138 | CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34+ hemopoietic progenitors cells. <i>Leukemia</i> , 2014, 28, 705-708. | 7.2 | 10 |
| 139 | Genetic characterization of p27 ^{kip1} and stathmin in controlling cell proliferation in vivo. <i>Cell Cycle</i> , 2014, 13, 3100-3111. | 2.6 | 34 |
| 140 | Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2014, 7, 79. | 17.0 | 22 |
| 141 | Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. <i>Blood</i> , 2014, 124, 3831-3833. | 1.4 | 27 |
| 142 | Microenvironmental Interactions in Chronic Lymphocytic Leukemia: The Master Role of CD49d. <i>Seminars in Hematology</i> , 2014, 51, 168-176. | 3.4 | 32 |
| 143 | Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 2139-2147. | 1.4 | 302 |
| 144 | NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <i>Annals of Hematology</i> , 2014, 93, 1765-1774. | 1.8 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | CD49d Is the Strongest Flow Cytometry-Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 897-904. | 1.6 | 162 |
| 146 | BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrnas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4495-4495. | 1.4 | 1 |
| 147 | Bendamustine Improves Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) According to Different Clinical and Biological Prognostic Factors. <i>Blood</i> , 2014, 124, 5668-5668. | 1.4 | 1 |
| 148 | Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. <i>ELife</i> , 2014, 3, . | 6.0 | 43 |
| 149 | NOTCH1 Mutations Are Associated with Low CD20 Expression in Chronic Lymphocytic Leukemia: Evidences for a NOTCH1-Mediated Epigenetic Regulatory Mechanism. <i>Blood</i> , 2014, 124, 296-296. | 1.4 | 5 |
| 150 | A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3300-3300. | 1.4 | 0 |
| 151 | NOTCH1 Mutations Are Associated with High CD49d Expression in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 1978-1978. | 1.4 | 0 |
| 152 | Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 295-295. | 1.4 | 1 |
| 153 | Recombinant Human Erythropoietin (RHuEpo) and Granular Colony Stimulating Factor (G-CSF) in hepatitis C virus (HCV) related to mixed cryoglobulinaemia associated to membranoproliferative glomerulonephritis type I: a case report description. <i>Infezioni in Medicina</i> , 2014, 22, 337-41. | 1.1 | 2 |
| 154 | Promoter methylation patterns in Richter syndrome affect stem cell maintenance and cell cycle regulation and differ from <i>de novo</i> diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 194-204. | 2.5 | 19 |
| 155 | Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , 2013, 122, 2673-2682. | 1.4 | 208 |
| 156 | Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 1403-1412. | 1.4 | 420 |
| 157 | Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 415-418. | 2.5 | 14 |
| 158 | Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013, 6, 83. | 17.0 | 14 |
| 159 | ARHGDI1, a mutant TP53-associated RhoGDP dissociation inhibitor, is overexpressed in gene expression profiles of TP53 disrupted chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2013, 161, 596-599. | 2.5 | 3 |
| 160 | Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4902-4905. | 1.4 | 113 |
| 161 | CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. <i>Blood</i> , 2013, 122, 3317-3321. | 1.4 | 48 |
| 162 | Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <i>Hematological Oncology</i> , 2013, 31, 88-95. | 1.7 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. PLoS ONE, 2013, 8, e74216. | 2.5 | 34 |
| 164 | TLR9 signaling defines distinct prognostic subsets in CLL. Frontiers in Bioscience - Landmark, 2013, 18, 371. | 3.0 | 17 |
| 165 | Clinical Impact Of Small TP53 Mutated Subclones In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 116-116. | 1.4 | 1 |
| 166 | Genomic Aberrations Dramatically Improve The Strong Prognostic Impact Of IGHV Mutational Status In Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 1370-1370. | 1.4 | 1 |
| 167 | CD49d Is The Strongest Flow Cytometry-Based Predictor Of Overall Survival In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 672-672. | 1.4 | 2 |
| 168 | Chronic Lymphocytic Leukemia Cells With Trisomy 12 Home To The Bone Marrow In a CXCR4-Independent Manner and Are Prone To Proliferate In Vitro. Blood, 2013, 122, 870-870. | 1.4 | 0 |
| 169 | The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia, 2012, 26, 1301-1312. | 7.2 | 78 |
| 170 | Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy. Current Pharmaceutical Design, 2012, 18, 3323-3334. | 1.9 | 17 |
| 171 | The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells. Blood, 2012, 119, 2106-2109. | 1.4 | 11 |
| 172 | Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood, 2012, 119, 2854-2862. | 1.4 | 257 |
| 173 | CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. Haematologica, 2012, 97, 279-287. | 3.5 | 32 |
| 174 | The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development. Journal of Experimental Medicine, 2012, 209, 1537-1551. | 8.5 | 363 |
| 175 | The miR-17 ^{1/492} family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia, 2012, 26, 1584-1593. | 7.2 | 77 |
| 176 | Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. Haematologica, 2012, 97, 849-853. | 3.5 | 14 |
| 177 | Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood, 2012, 119, 521-529. | 1.4 | 394 |
| 178 | Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. Hematological Oncology, 2012, 30, 46-49. | 1.7 | 20 |
| 179 | Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. International Journal of Cancer, 2012, 130, 3006-3010. | 5.1 | 28 |
| 180 | IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. Journal of Translational Medicine, 2012, 10, 18. | 4.4 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | CD49d Is Overexpressed in Trisomy 12 Chronic Lymphocytic Leukemia by an Epigenetic-Dependent Transcriptional Control. <i>Blood</i> , 2012, 120, 929-929. | 1.4 | 1 |
| 182 | Clinical Significance of NOTCH1 mutations in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2870-2870. | 1.4 | 0 |
| 183 | Clinical Significance of 13q14 Number of Deleted Cells in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 4581-4581. | 1.4 | 0 |
| 184 | Circulating CLL Cells Expressing CD49d Display a Phospho-Proteomic Profile Consistent with a Constitutive Receptor Engagement by Blood-Borne Ligands. <i>Blood</i> , 2012, 120, 930-930. | 1.4 | 0 |
| 185 | The Elastin Microfibril Interfacer-1 (EMILIN-1) Is a Ligand for CD49d in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2012, 120, 1772-1772. | 1.4 | 0 |
| 186 | Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 712-712. | 1.4 | 0 |
| 187 | The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , 2011, 117, 3391-3401. | 1.4 | 316 |
| 188 | Analysis of the chronic lymphocytic leukemia coding genome: role of <i>NOTCH1</i> mutational activation. <i>Journal of Experimental Medicine</i> , 2011, 208, 1389-1401. | 8.5 | 565 |
| 189 | Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. <i>Blood</i> , 2011, 118, 6904-6908. | 1.4 | 342 |
| 190 | Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604. | 1.4 | 173 |
| 191 | B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the <i>IGHV3</i> subgroup gene usage. <i>British Journal of Haematology</i> , 2011, 153, 3-14. | 2.5 | 30 |
| 192 | A variant of the <i>LRP4</i> gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2011, 152, 284-294. | 2.5 | 28 |
| 193 | Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 154, 590-599. | 2.5 | 40 |
| 194 | Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines. <i>Investigational New Drugs</i> , 2011, 29, 392-395. | 2.6 | 11 |
| 195 | Cluster analysis of immunophenotypic data: The example of chronic lymphocytic leukemia. <i>Immunology Letters</i> , 2011, 134, 137-144. | 2.5 | 17 |
| 196 | 13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 633-643. | 2.8 | 67 |
| 197 | Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2011, 29, 91-99. | 1.7 | 30 |
| 198 | Immunotherapeutic Maintenance Strategy Prolongs Response Duration and Overall Survival Preventing Relapse in Chronic Lymphocytic Leukemia (CLL),. <i>Blood</i> , 2011, 118, 3906-3906. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Abstract 1542: CD38 is physically associated with CD49d and enhances CD49d-mediated adhesion of B-Cell chronic lymphocytic leukemia cells. , 2011, , . | | 0 |
| 200 | Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome. <i>Blood</i> , 2011, 118, 2845-2845. | 1.4 | 0 |
| 201 | SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). <i>Blood</i> , 2011, 118, 263-263. | 1.4 | 1 |
| 202 | Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway. <i>Blood</i> , 2011, 118, 1359-1359. | 1.4 | 17 |
| 203 | Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010, 95, 1792-1796. | 3.5 | 91 |
| 204 | Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. <i>Blood</i> , 2010, 116, 2295-2303. | 1.4 | 126 |
| 205 | Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <i>Leukemia and Lymphoma</i> , 2010, 51, 822-838. | 1.3 | 9 |
| 206 | Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 116, 584-592. | 1.4 | 51 |
| 207 | CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. <i>Seminars in Cancer Biology</i> , 2010, 20, 416-423. | 9.6 | 28 |
| 208 | Genomic profiling of Richter's syndrome: recurrent lesions and differences with <i>de novo</i> diffuse large B-cell lymphomas. <i>Hematological Oncology</i> , 2010, 28, 62-67. | 1.7 | 46 |
| 209 | Analysis of the <i>REL</i> , <i>BCL11A</i> , and <i>MYCN</i> protooncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2010, 85, 541-544. | 4.1 | 13 |
| 210 | Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome. <i>American Journal of Hematology</i> , 2010, 85, 619-622. | 4.1 | 10 |
| 211 | <i>IGHD3</i> fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 149, 299-302. | 2.5 | 1 |
| 212 | Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38 ⁺ CD49d ⁺ chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2010, 150, 111-112. | 2.5 | 33 |
| 213 | <i>MDM4</i> (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53 ^{wild-type} CLL with a poor cytotoxic response to Nutlin-3. <i>British Journal of Haematology</i> , 2010, 150, 237-239. | 2.5 | 27 |
| 214 | The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. <i>Leukemia</i> , 2010, 24, 480-483. | 7.2 | 7 |
| 215 | A new freezing and storage procedure improves safety and viability of haematopoietic stem cells and neutrophil engraftment: a single institution experience. <i>Vox Sanguinis</i> , 2010, 98, 172-180. | 1.5 | 13 |
| 216 | Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. <i>Clinical Cancer Research</i> , 2010, 16, 620-628. | 7.0 | 44 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 95-106. | 1.3 | 16 |
| 218 | Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. <i>Journal of Translational Medicine</i> , 2010, 8, 23. | 4.4 | 19 |
| 219 | Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). <i>Blood</i> , 2010, 116, 1371-1371. | 1.4 | 2 |
| 220 | SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. <i>Blood</i> , 2010, 116, 3611-3611. | 1.4 | 4 |
| 221 | 13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 3578-3578. | 1.4 | 0 |
| 222 | Molecular History of Richter Syndrome: Origin From a Common Ancestor Cell Already Present at Chronic Lymphocytic Leukemia Diagnosis. <i>Blood</i> , 2010, 116, 2425-2425. | 1.4 | 1 |
| 223 | The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship. <i>Blood</i> , 2010, 116, 3601-3601. | 1.4 | 0 |
| 224 | Clinical Significance of CD69 Expression In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 3574-3574. | 1.4 | 0 |
| 225 | IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. <i>Blood</i> , 2010, 116, 2951-2951. | 1.4 | 0 |
| 226 | Normal Fish Cytogenetics and 13q Deletions Unveil Marked Biological and Clinical Heterogeneity In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 2692-2692. | 1.4 | 0 |
| 227 | Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementary Table). <i>Current Cancer Drug Targets</i> , 2009, 9, 510-518. | 1.6 | 11 |
| 228 | The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness. <i>Clinical Cancer Research</i> , 2009, 15, 995-1004. | 7.0 | 284 |
| 229 | Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Clinical Cancer Research</i> , 2009, 15, 4415-4422. | 7.0 | 189 |
| 230 | CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. <i>Cancer Research</i> , 2009, 69, 4001-4009. | 0.9 | 153 |
| 231 | How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2009, 27, 186-189. | 1.7 | 3 |
| 232 | Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506. | 2.5 | 106 |
| 233 | The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. <i>British Journal of Haematology</i> , 2009, 146, 64-75. | 2.5 | 136 |
| 234 | Human immunodeficiency virus-associated precursor T-lymphoblastic leukemia/lymphoblastic lymphoma: report of a case and review of the literature. <i>Human Pathology</i> , 2009, 40, 1045-1049. | 2.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. <i>Journal of Translational Medicine</i> , 2009, 7, 76. | 4.4 | 41 |
| 236 | Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. <i>Blood</i> , 2009, 113, 4300-4308. | 1.4 | 83 |
| 237 | The Amount of Spontaneous Apoptosis Is An Independent Strong Disease Progression Indicator in B-Cell Chronic Lymphocytic Leukemia (B-CLL). <i>Blood</i> , 2009, 114, 1252-1252. | 1.4 | 2 |
| 238 | Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 2008, 112, 119-128. | 4.1 | 86 |
| 239 | Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10. <i>Leukemia</i> , 2008, 22, 224-226. | 7.2 | 8 |
| 240 | Preclinical ex vivo expansion of peripheral blood CD34+ selected cells from cancer patients mobilized with combination chemotherapy and granulocyte colony-stimulating factor. <i>Vox Sanguinis</i> , 2008, 94, 342-350. | 1.5 | 5 |
| 241 | Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait. <i>British Journal of Haematology</i> , 2008, 141, 734-736. | 2.5 | 21 |
| 242 | Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2008, 142, 202-215. | 2.5 | 206 |
| 243 | Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. <i>British Journal of Haematology</i> , 2008, 143, 532-536. | 2.5 | 58 |
| 244 | APE/Ref-1 makes fine-tuning of CD40-induced B cell proliferation. <i>Molecular Immunology</i> , 2008, 45, 3731-3739. | 2.2 | 11 |
| 245 | CD49d expression in chronic lymphocytic leukemia: a prognostic parameter and a therapeutic target. <i>Future Oncology</i> , 2008, 4, 355-358. | 2.4 | 9 |
| 246 | CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. <i>Haematologica</i> , 2008, 93, 1575-1579. | 3.5 | 72 |
| 247 | Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 865-873. | 1.4 | 226 |
| 248 | Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Blood</i> , 2008, 112, 778-778. | 1.4 | 0 |
| 249 | Comprehensive characterization of IGHV3-21 ⁺ expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007, 109, 2989-2998. | 1.4 | 62 |
| 250 | Laminin-332 (Laminin-5) is the major motility ligand for B cell chronic lymphocytic leukemia. <i>Matrix Biology</i> , 2007, 26, 473-484. | 3.6 | 11 |
| 251 | Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. <i>Leukemia</i> , 2007, 21, 965-972. | 7.2 | 57 |
| 252 | Identification of New Recurrent Lesions and Clinical Subsets by Genome-Wide DNA Profiling in Chronic Lymphocytic Leukemia with 17p Deletion.. <i>Blood</i> , 2007, 110, 4696-4696. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. Blood, 2007, 110, 3089-3089. | 1.4 | 0 |
| 254 | Molecular, Phenotypic and Clinical Predictors of Richter Syndrome (RS) in Chronic Lymphocytic Leukemia (CLL).. Blood, 2007, 110, 3086-3086. | 1.4 | 1 |
| 255 | Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood, 2006, 108, 853-861. | 1.4 | 171 |
| 256 | Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. Journal of Translational Medicine, 2006, 4, 11. | 4.4 | 9 |
| 257 | Concomitant chronic lymphocytic leukemia and acute myeloid leukemia: Evidence of simultaneous expansion of two independent clones. Leukemia and Lymphoma, 2006, 47, 885-889. | 1.3 | 18 |
| 258 | CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. Leukemia, 2006, 20, 523-525. | 7.2 | 51 |
| 259 | Reply to Pittner et al.. Leukemia, 2006, 20, 528-529. | 7.2 | 10 |
| 260 | Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). Leukemia Research, 2006, 30, 1197-1199. | 0.8 | 17 |
| 261 | The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia, 2006, 20, 1783-1789. | 7.2 | 117 |
| 262 | ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations. Cytometry Part B - Clinical Cytometry, 2006, 70B, 284-292. | 1.5 | 38 |
| 263 | A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. Journal of Cellular Physiology, 2006, 207, 354-363. | 4.1 | 49 |
| 264 | Gene Expression Profiling (GEP) of CD38-Expressing/Unmutated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Cells by Using a Statistical Approach Suitable for Analysis of Unbalanced Datasets.. Blood, 2006, 108, 2089-2089. | 1.4 | 0 |
| 265 | Mutational status of IgVH genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection?. Leukemia, 2005, 19, 1490-1492. | 7.2 | 23 |
| 266 | Epigenetic Immunomodulation of Hematopoietic Malignancies. Seminars in Oncology, 2005, 32, 503-510. | 2.2 | 17 |
| 267 | Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance. Journal of Immunological Methods, 2005, 305, 20-32. | 1.4 | 17 |
| 268 | Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: Immunotherapeutic implications. Journal of Cellular Physiology, 2005, 202, 474-477. | 4.1 | 23 |
| 269 | Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. Journal of Cellular Physiology, 2005, 204, 113-123. | 4.1 | 30 |
| 270 | The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer, 2005, 104, 2743-2752. | 4.1 | 45 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Activation-Induced Cytidine Deaminase and CD38 Expression in B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma and Myeloma, 2005, 6, 251-252. | 1.4 | 3 |
| 272 | Mutational Status of IgVH Genes in B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Prognosis: Percent Mutations or Evaluation of Antigen-Driven Selection?. Blood, 2005, 106, 2106-2106. | 1.4 | 0 |
| 273 | CD26 Expression Correlates with a Reduced Sensitivity to 2-Deoxycoformycin-Induced Growth Inhibition and Apoptosis in T-Cell Leukemia/Lymphomas. Clinical Cancer Research, 2004, 10, 508-520. | 7.0 | 25 |
| 274 | Hepatitis C virus infection does not prevent autologous bone marrow transplantation in HIV-related non-Hodgkin's lymphoma. Aids, 2004, 18, 1859-1861. | 2.2 | 2 |
| 275 | CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*. British Journal of Haematology, 2004, 125, 203-212. | 2.5 | 26 |
| 276 | Analysis of IgVH gene mutations in B-cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. British Journal of Haematology, 2004, 126, 29-42. | 2.5 | 54 |
| 277 | Interactions Between Tissue Fibroblasts in Lymph Nodes and Hodgkin/Reed-Sternberg Cells. Leukemia and Lymphoma, 2004, 45, 1731-1739. | 1.3 | 57 |
| 278 | Mutational Status of IgVH Genes Consistent with Antigen-Driven Selection but Not Percent of Mutations Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma and Myeloma, 2004, 5, 123-126. | 2.1 | 9 |
| 279 | Error-Prone DNA Polymerases iota and beta Are Over-Expressed in B-CLL Cells: Correlation with Specific IgVH Point-Mutations and Implication for the Pathogenesis of Intraclonal IgVH Diversification.. Blood, 2004, 104, 950-950. | 1.4 | 1 |
| 280 | Addition of Rituximab to Fludarabine Improves Progression Free Survival in Untreated ZAP-70 Negative Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 477-477. | 1.4 | 1 |
| 281 | ZAP-70 Protein Retains Its Prognostic Significance within Interphase Cytogenetic Groups in B-Cell Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2004, 104, 2806-2806. | 1.4 | 1 |
| 282 | Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica, 2004, 89, 1468-75. | 3.5 | 18 |
| 283 | Interleukin-3 Receptors in Hodgkin's Disease. American Journal of Pathology, 2003, 162, 355-357. | 3.8 | 4 |
| 284 | The role of interleukin-3 and stem cell factor in classical Hodgkin disease. Blood, 2003, 101, 376-376. | 1.4 | 5 |
| 285 | 5-Aza-2-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. Blood, 2003, 101, 4644-4646. | 1.4 | 78 |
| 286 | Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. Journal of Cell Biology, 2002, 158, 1133-1144. | 5.2 | 83 |
| 287 | Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood, 2002, 99, 856-862. | 1.4 | 155 |
| 288 | Expression of Functional Interleukin-3 Receptors on Hodgkin and Reed-Sternberg Cells. American Journal of Pathology, 2002, 160, 585-596. | 3.8 | 56 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts. <i>Experimental Hematology</i> , 2002, 30, 1283-1292. | 0.4 | 31 |
| 290 | Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells. <i>British Journal of Haematology</i> , 2002, 117, 59-69. | 2.5 | 10 |
| 291 | Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. <i>British Journal of Haematology</i> , 2002, 117, 366-372. | 2.5 | 106 |
| 292 | Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. <i>British Journal of Haematology</i> , 2002, 118, 1055-1064. | 2.5 | 22 |
| 293 | A novel bcl-1/JH breakpoint from a patient affected by mantle cell lymphoma extends the major translocation cluster. <i>Journal of Pathology</i> , 2002, 197, 256-263. | 4.5 | 13 |
| 294 | Expression and Localization of the Homeodomain-Containing Protein HEX in Human Thyroid Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1376-1383. | 3.6 | 29 |
| 295 | CD30L up-regulates CD30 and IL-4 expression by T cells. <i>FEBS Letters</i> , 2001, 508, 418-422. | 2.8 | 20 |
| 296 | In vitro and in vivo effects of 2-â€²-deoxycoformycin (Pentostatin) on tumour cells from human Î³Î³+ T-cell malignancies. <i>British Journal of Haematology</i> , 2000, 110, 188-196. | 2.5 | 30 |
| 297 | Normalizing Complementary DNA by Quantitative Reverse Transcriptase-â€²-Polymerase Chain Reaction of Î²2-Microglobulin: Molecular Monitoring of Minimal Residual Disease in Acute Promyelocytic Leukemia. <i>Diagnostic Molecular Pathology</i> , 2000, 9, 98-109. | 2.1 | 19 |
| 298 | CD30 Ligand (CD30L)-Expressing Acute Myeloid Leukemias: A New Model of Paracrine Interactions for the Regulation of Blast Cells Proliferation. <i>Leukemia and Lymphoma</i> , 1999, 35, 21-35. | 1.3 | 11 |
| 299 | Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. <i>British Journal of Haematology</i> , 1999, 104, 152-162. | 2.5 | 22 |
| 300 | The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up-regulated upon differentiation. <i>British Journal of Haematology</i> , 1999, 105, 225-240. | 2.5 | 19 |
| 301 | Frequent Expression of the Variant CD30 in Human Malignant Myeloid and Lymphoid Neoplasms. <i>American Journal of Pathology</i> , 1999, 155, 2029-2041. | 3.8 | 21 |
| 302 | Hodgkin's disease: A disorder of dysregulated cellular cross-talk. <i>Biotherapy (Dordrecht)</i> , 1999, 11, 19-22. | 0.7 | 19 |
| 303 | Differential expression of the RET gene in human acute myeloid leukemia. <i>Annals of Hematology</i> , 1998, 77, 207-210. | 1.8 | 12 |
| 304 | The role of eosinophils in the pathobiology of Hodgkin's disease. <i>Annals of Oncology</i> , 1997, 8, S89-S96. | 1.2 | 48 |
| 305 | Competitive reverse-transcriptase PCR: a useful alternative to Northern blotting for quantitative estimation of relative abundances of specific mRNAs in precious samples. <i>Biochemical Journal</i> , 1997, 325, 565-567. | 3.7 | 15 |
| 306 | CD40/CD40 Ligand Interactions in Normal, Reactive and Malignant Lympho-Hematopoietic Tissues. <i>Leukemia and Lymphoma</i> , 1997, 24, 393-422. | 1.3 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997, 89, 3787-3794. | 1.4 | 55 |
| 308 | CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin. <i>Blood</i> , 1997, 89, 2048-2059. | 1.4 | 110 |
| 309 | Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997, 89, 3787-3794. | 1.4 | 1 |
| 310 | Reducing chemotherapy-associated toxicity in elderly cancer patients. <i>Cancer Treatment Reviews</i> , 1996, 22, 223-244. | 7.7 | 14 |
| 311 | In Vitro Cellular Systems for Studying OC Function and Differentiation: Primary OC Cultures and the FLG 29.1 Model. , 1996, 2, 277-306. | | 2 |
| 312 | In vitro structural and functional relationships between preosteoclastic and bone endothelial cells: A juxtacrine model for migration and adhesion of osteoclast precursors. <i>Journal of Cellular Physiology</i> , 1995, 162, 199-212. | 4.1 | 25 |
| 313 | Phorbol ester induced osteoclast-like differentiation of a novel human leukemic cell line (FLG 29.1).. <i>Journal of Cell Biology</i> , 1992, 116, 437-447. | 5.2 | 76 |
| 314 | Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site-selective 8-chloroadenosine 3',5'-cyclic monophosphate.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 8884-8888. | 7.1 | 24 |
| 315 | Follicular Lymphoma of Compartmentalized Small Cleaved Center Cells and Mantle Zone Lymphocytes: Evidence for a Common Derivation. <i>American Journal of Clinical Pathology</i> , 1992, 98, 437-448. | 0.7 | 21 |
| 316 | EXPRESSION OF NATURAL KILLER ANTIGENS IN A SUBSET OF "ON-T. NON-B LYMPHOMA/LEUKAEMIA WITH HISTIOCYTIC FEATURES". <i>British Journal of Haematology</i> , 1990, 76, 444-448. | 2.5 | 19 |
| 317 | The transforming growth factor-beta in the regulation of normal and leukemic myelopoiesis. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1990, 2, 385-398. | 0.7 | 0 |
| 318 | Differential sensitivity to (dl)-5-methyltetrahydrofolate of normal CFU-GM and HL-60 cells. <i>Leukemia Research</i> , 1989, 13, 595-598. | 0.8 | 2 |
| 319 | In vitro chemosensitivity testing of leukemic cells: Development of a semiautomated colorimetric assay. <i>Hematological Oncology</i> , 1989, 7, 243-253. | 1.7 | 23 |
| 320 | In vitro chemosensitivity testing of leukemic cells: Prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia. <i>Hematological Oncology</i> , 1989, 7, 287-293. | 1.7 | 39 |
| 321 | Induction of Differentiation of HL-60 Cells Along the Monocytic Pathway by 5-Methyltetrahydrofolate. <i>Journal of Chemotherapy</i> , 1989, 1, 359-364. | 1.5 | 2 |
| 322 | Clonogenic growth of acute non-lymphocytic leukemia cells in serum-free medium. <i>Experientia</i> , 1988, 44, 903-906. | 1.2 | 0 |
| 323 | Proliferation and cell loss of human leukemic cell subpopulations in liquid culture. <i>Experientia</i> , 1988, 44, 245-247. | 1.2 | 2 |
| 324 | B-cell chronic lymphocytic leukemia. , 0, , 786-792. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 325 | Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights. <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 3 |